These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 31695802)

  • 1. Peptide-based materials for cancer immunotherapy.
    Zhang L; Huang Y; Lindstrom AR; Lin TY; Lam KS; Li Y
    Theranostics; 2019; 9(25):7807-7825. PubMed ID: 31695802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peptide-Based Treatment: A Promising Cancer Therapy.
    Xiao YF; Jie MM; Li BS; Hu CJ; Xie R; Tang B; Yang SM
    J Immunol Res; 2015; 2015():761820. PubMed ID: 26568964
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sulfonium-Stapled Peptides-Based Neoantigen Delivery System for Personalized Tumor Immunotherapy and Prevention.
    Zhang Y; Jiang L; Huang S; Lian C; Liang H; Xing Y; Liu J; Tian X; Liu Z; Wang R; An Y; Lu F; Pan Y; Han W; Li Z; Yin F
    Adv Sci (Weinh); 2024 Jun; 11(24):e2307754. PubMed ID: 38605600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Composite peptide-based vaccines for cancer immunotherapy (Review).
    Yang J; Zhang Q; Li K; Yin H; Zheng JN
    Int J Mol Med; 2015 Jan; 35(1):17-23. PubMed ID: 25395173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The present status and future prospects of peptide-based cancer vaccines.
    Hirayama M; Nishimura Y
    Int Immunol; 2016 Jul; 28(7):319-28. PubMed ID: 27235694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer Immunotherapy: Priming the Host Immune Response with Live Attenuated
    Hernández-Luna MA; Luria-Pérez R
    J Immunol Res; 2018; 2018():2984247. PubMed ID: 30302344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beyond Just Peptide Antigens: The Complex World of Peptide-Based Cancer Vaccines.
    Stephens AJ; Burgess-Brown NA; Jiang S
    Front Immunol; 2021; 12():696791. PubMed ID: 34276688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of optimized cryptic peptides for immunotherapy.
    Menez-Jamet J; Kosmatopoulos K
    IDrugs; 2009 Feb; 12(2):98-102. PubMed ID: 19204883
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecularly defined vaccines for cancer immunotherapy, and protective T cell immunity.
    Speiser DE; Romero P
    Semin Immunol; 2010 Jun; 22(3):144-54. PubMed ID: 20413326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. mRNA vaccine for cancer immunotherapy.
    Miao L; Zhang Y; Huang L
    Mol Cancer; 2021 Feb; 20(1):41. PubMed ID: 33632261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Particulate Systems Based on Poly(Lactic-co-Glycolic)Acid (pLGA) for Immunotherapy of Cancer.
    Rahimian S; Fransen MF; Kleinovink JW; Amidi M; Ossendorp F; Hennink WE
    Curr Pharm Des; 2015; 21(29):4201-16. PubMed ID: 26323429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insights into peptide-based vaccine design for cancer immunotherapy.
    Lazoura E; Apostolopoulos V
    Curr Med Chem; 2005; 12(13):1481-94. PubMed ID: 15974981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DNA vaccines to attack cancer: Strategies for improving immunogenicity and efficacy.
    Tiptiri-Kourpeti A; Spyridopoulou K; Pappa A; Chlichlia K
    Pharmacol Ther; 2016 Sep; 165():32-49. PubMed ID: 27235391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Personalized neoantigen vaccination with synthetic long peptides: recent advances and future perspectives.
    Chen X; Yang J; Wang L; Liu B
    Theranostics; 2020; 10(13):6011-6023. PubMed ID: 32483434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Manipulation of Innate and Adaptive Immunity through Cancer Vaccines.
    Sayour EJ; Mitchell DA
    J Immunol Res; 2017; 2017():3145742. PubMed ID: 28265580
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhancing cancer immunotherapy by intracellular delivery of cell-penetrating peptides and stimulation of pattern-recognition receptor signaling.
    Wang HY; Wang RF
    Adv Immunol; 2012; 114():151-76. PubMed ID: 22449781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heat shock protein--peptide complexes as immunotherapy for human cancer.
    Przepiorka D; Srivastava PK
    Mol Med Today; 1998 Nov; 4(11):478-84. PubMed ID: 9857367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. WT1 peptide vaccine as a paradigm for "cancer antigen-derived peptide"-based immunotherapy for malignancies: successful induction of anti-cancer effect by vaccination with a single kind of WT1 peptide.
    Oka Y; Tsuboi A; Fujiki F; Li Z; Nakajima H; Hosen N; Shirakata T; Nishida S; Oji Y; Kawase I; Sugiyama H
    Anticancer Agents Med Chem; 2009 Sep; 9(7):787-97. PubMed ID: 19538172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peptide-based vaccines for cancer: realizing their potential.
    Kanodia S; Kast WM
    Expert Rev Vaccines; 2008 Dec; 7(10):1533-45. PubMed ID: 19053209
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent advances and challenges of repurposing nanoparticle-based drug delivery systems to enhance cancer immunotherapy.
    Lim S; Park J; Shim MK; Um W; Yoon HY; Ryu JH; Lim DK; Kim K
    Theranostics; 2019; 9(25):7906-7923. PubMed ID: 31695807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.